Harry Uy, MD
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1962541466
Payments from drug & device makers
Across 342 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Amgen$1K
- Dexcom, Inc.$653
- Radius Health, Inc.$624
- Corcept Therapeutics$457
- Abbott$443
- plus $4K from 35 others
What the payments were for
- Consulting fees$1752%
- Food & beverage$8,51597%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 53 | $1,142 |
| Amgen | 39 | $1,109 |
| Dexcom, Inc. | 17 | $653 |
| Radius Health, Inc. | 22 | $624 |
| Corcept Therapeutics | 16 | $457 |
| Abbott | 15 | $443 |
| Medtronic(2 entities) | 10 | $395 |
| Novo Nordisk | 20 | $395 |
| Cequr Corporation | 3 | $364 |
| Tandem Diabetes Care, Inc. | 10 | $330 |
| BETA Bionics, Inc. | 12 | $325 |
| Boehringer Ingelheim | 13 | $286 |
| Recordati_rare_diseases_inc. | 6 | $202 |
| Mannkind Corporation | 8 | $175 |
| Bayer | 9 | $170 |
| AbbVie | 10 | $150 |
| Sanofi-aventis U.S. LLC | 8 | $149 |
| Intuity Medical Inc | 10 | $149 |
| Insulet Corporation | 6 | $139 |
| Novartis | 7 | $131 |
| Xeris Pharmaceuticals, Inc. | 7 | $125 |
| Amneal Pharmaceuticals LLC | 7 | $114 |
| Kyowa Kirin, Inc. | 4 | $94 |
| Acella Pharmaceuticals, LLC | 4 | $72 |
| Ascendis Pharma Endocrinology Inc | 3 | $67 |
| Tolmar, Inc. | 4 | $63 |
| Soleno Therapeutics, Inc. | 2 | $58 |
| AstraZeneca | 3 | $50 |
| Chiesi USA, Inc. | 2 | $49 |
| Neurocrine Biosciences, Inc. | 1 | $35 |
| Sequel Med Tech, LLC | 1 | $26 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| Pfizer | 1 | $24 |
| Almatica Pharma LLC | 1 | $23 |
| Sandoz | 1 | $22 |
| Acerus Pharmaceuticals Corporation | 1 | $22 |
| Antares Pharma, Inc. | 1 | $20 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| RGH Enterprises LLC | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$351
- Prolia$175
- MINIMED 780G$151
- DEXCOM G7 GSS (161)$150
- DEXCOM STELO GLUCOSE BIOSENSOR$150
- Korlym$128
- TEPEZZA$123
- MOUNJARO$122
- t:slim X2 Insulin Pump with Control-IQ$121
- MINIMED 770G$120
- Tymlos$120
- EVENITY$118
- Repatha$112
- ISTURISA$100
How this compares
$8,737 in reported general payments places this provider in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 123 | $206,612 |
| JardianceEmpagliflozin | 58 | $94,644 |
| TymlosAbaloparatide | 26 | $91,216 |
| OzempicSemaglutide | 57 | $69,760 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $45,516 |
| MounjaroTirzepatide | 34 | $42,230 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $37,049 |
| JanuviaSitagliptin Phosphate | 20 | $28,582 |
| FarxigaDapagliflozin Propanediol | 15 | $24,911 |
| TradjentaLinagliptin | 22 | $19,207 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $18,414 |
| Humalog Kwikpen U-100Insulin Lispro | 42 | $16,777 |
| Levothyroxine Sodium | 1,329 | $15,918 |
| Ibandronate Sodium | 397 | $12,529 |
| Novolog FlexpenInsulin Aspart | 30 | $11,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia | $1,109 | $206,612123 claims |
| Boehringer IngelheimJardiance, Tradjenta | $286 | $113,85180 claims |
| Radius Health, Inc.Tymlos | $624 | $91,21626 claims |
| Novo NordiskOzempic | $395 | $69,76057 claims |
| Lilly USA, LLCMounjaro | $1,142 | $42,23034 claims |
| AstraZenecaFarxiga | $50 | $24,91115 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $114 | $15,9181,329 claims |
| AbbVieSynthroid | $150 | $11,013151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Mark KipnesSan Antonio$10.3M
- Ralph DefronzoSan Antonio$4.8M
- Eugenio CersosimoSan Antonio$4M
- Devjit TripathySan Antonio$1.5M
- Carolina Solis-HerreraSan Antonio$1.3M
- Firas AkhrassSan Antonio$900K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.